Drug Trial Radar · NCT04991506
A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jun 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Oct 15, 2021
Primary completion
May 17, 2024
Study completion May 17, 2024
Sponsor
- Lead sponsor
- Elpiscience Biopharma, Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Shanghai Junshi Bioscience Co., Ltd.
- First posted
- Aug 5, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerance, Dose-Limiting Toxicity (DLT), Maximum tolerated dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of ES102 (OX40 agonist) in combination with JS001 (anti-PD-1 checkpoint inhibitor) in patients with advanced solid tumors.
Conditions
- Solid Tumor
- Neoplasms
- Malignant Tumor
Interventions
ES102Drug
The active ingredient of ES102 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4)
JS001Drug
JS001 is administered via intravenous injection once every 21 days, every 21 days as a treatment cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- MTDTime frame: 2-4 years
- Frequency and severity of adverse events of ES102 in combination with JS001Time frame: 2-4 years
- RP2DTime frame: 2-4 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Jilin Cancer Hospital
Changchun, Jilin, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.